Clinical Trials Logo
  1. Home
  2. Drug Reaction
  3. NCT03585946

Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis

Stevens-Johnson Syndrome Clinical Trial

Official title:
A Prospective Multicenter Cohort Study Assessing Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis

Clinical Trial Summary

This is a prospective, multicenter cohort observational; study to compare treatment outcomes in patients admitted to the hospital with Stevens-Johnsons Syndrome/Toxic Epidermolysis, aiming to assess the utility of medical management. The hypothesis of this study is that one or more treatment options will demonstrate improved patient outcomes. The primary objectives are cessation of progression of disease, time to complete re-epithelialization, length of stay, and mortality rate in the treatment groups as compared to those receiving supportive care alone. Exploratory analyses will assess the cause, risk factors, and severity prediction factors associated with the disease.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03585946
Study type Observational
Source Massachusetts General Hospital
Contact
Status Not yet recruiting
Phase
Start date January 1, 2024
Completion date December 31, 2028
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03659227 - Drug Reactions Sampling (COLLECTIONTOXIDERMIES)
Completed NCT01696500 - Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. Phase 3
Terminated NCT02037347 - Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis Phase 1/Phase 2
Withdrawn NCT02126020 - Topical Infliximab in Autoimmune Eyes With Keratoprosthesis Phase 1/Phase 2
Active, not recruiting NCT05520086 - Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis. Phase 1/Phase 2
Completed NCT06263140 - Vitamin D Levels in Non-immediate Drug Hypersensitivity Case-control Study
Available NCT02149732 - Clinical Trial on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation Phase 1/Phase 2
Recruiting NCT05284929 - Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population
Recruiting NCT02987257 - NATIENS: Optimal Management and Mechanisms of SJS/TEN Phase 3
Completed NCT02945176 - Safety and Performance Study of the ARGOS-IO System in Patients Undergoing Boston Keratoprosthesis Implantation N/A
Recruiting NCT04313725 - Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren's Syndrome, and Graft Vs Host Disease N/A
Recruiting NCT03046914 - HLA-B*5801 Screening to Prevent Allopurinol-induced Severe Cutaneous Adverse Reaction N/A
Completed NCT01488396 - Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye Phase 4
Withdrawn NCT01256489 - Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS) Phase 1/Phase 2
Active, not recruiting NCT01122303 - Corneal Epitheliotropic Factors in Autologous Serum Eye Drops in Nonautoimmune and Stevens-Johnson Syndrome With Dry Eye N/A
Recruiting NCT05145959 - Meibomian Gland Probing in the Sub-Acute Phase of Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis N/A
Completed NCT00844038 - Stevens-Johnson Syndrome Antimicrobial N/A